全文获取类型
收费全文 | 317篇 |
免费 | 42篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 21篇 |
基础医学 | 13篇 |
口腔科学 | 12篇 |
临床医学 | 49篇 |
内科学 | 56篇 |
皮肤病学 | 3篇 |
神经病学 | 20篇 |
特种医学 | 41篇 |
外科学 | 21篇 |
综合类 | 5篇 |
预防医学 | 99篇 |
眼科学 | 4篇 |
药学 | 11篇 |
肿瘤学 | 15篇 |
出版年
2023年 | 2篇 |
2022年 | 5篇 |
2021年 | 6篇 |
2020年 | 5篇 |
2019年 | 3篇 |
2018年 | 8篇 |
2017年 | 18篇 |
2016年 | 14篇 |
2015年 | 9篇 |
2014年 | 11篇 |
2013年 | 29篇 |
2012年 | 19篇 |
2011年 | 11篇 |
2010年 | 13篇 |
2009年 | 14篇 |
2008年 | 10篇 |
2007年 | 13篇 |
2006年 | 10篇 |
2005年 | 9篇 |
2004年 | 7篇 |
2003年 | 5篇 |
2002年 | 4篇 |
2001年 | 8篇 |
1999年 | 6篇 |
1998年 | 8篇 |
1997年 | 12篇 |
1996年 | 11篇 |
1995年 | 12篇 |
1994年 | 15篇 |
1993年 | 6篇 |
1992年 | 6篇 |
1991年 | 3篇 |
1989年 | 7篇 |
1988年 | 6篇 |
1987年 | 6篇 |
1986年 | 4篇 |
1985年 | 2篇 |
1984年 | 6篇 |
1983年 | 4篇 |
1982年 | 4篇 |
1980年 | 2篇 |
1975年 | 1篇 |
1969年 | 2篇 |
1968年 | 1篇 |
1965年 | 1篇 |
1963年 | 1篇 |
1957年 | 1篇 |
1943年 | 2篇 |
1939年 | 1篇 |
1937年 | 1篇 |
排序方式: 共有371条查询结果,搜索用时 15 毫秒
31.
A. Saratzis N. E. M. Jaspers B. Gwilym O. Thomas A. Tsui R. Lefroy M. Parks V. Htun Z. Mera A. Thatcher D. Bosanquet R. Forsythe R. Benson N. Dattani G. Dovell T. Lane J. Shalhoub D. Sidloff F. L. J. Visseren J. A. N. Dorresteijn T. Richards Vascular Endovascular Research Network Collaborators 《The British journal of surgery》2019,106(9):1168-1177
32.
33.
Charlene Compher PhD RD CNSC LDN FASPEN Stanley J. Dudrick MD John R. Wesley MD FACS FAAP FASPEN Ainsley Malone MS RD LD CNSC FAND FASPEN Gordon S. Sacks PharmD BCNSP FCCP M. Molly McMahon MD Marion F. Winkler PhD RD LDN CNSC FASPEN Kris M. Mogensen MS RD LDN CNSC Arlet Kurkchubasche MD Meghan A. Arnold MD Hua Yang MD PhD Allison B. Blackmer PharmD BCPS Carol Braunschweig PhD RD Theresa Han‐Markey MS RD M. Luisa Partipilo PharmD BCNSP Mary Beth Harris MPH RD CSP CNSC Deb Kovacevich MPH BSN RN Bonnie Peters RN Alexis Cantwell Mary Ann Fithian 《JPEN. Journal of parenteral and enteral nutrition》2016,40(8):1079-1086
34.
Matthews DC; Appelbaum FR; Eary JF; Fisher DR; Durack LD; Bush SA; Hui TE; Martin PJ; Mitchell D; Press OW 《Blood》1995,85(4):1122-1131
In an attempt to decrease the relapse rate after bone marrow transplantation (BMT) for advanced acute leukemia, we initiated studies using 131I-labeled anti-CD45 antibody (BC8) to deliver radiation specifically to hematopoietic tissues, followed by a standard transplant preparative regimen. Biodistribution studies were performed in 23 patients using 0.5 mg/kg trace 131I-labeled BC8 antibody. The BC8 antibody was cleared rapidly from plasma with an initial disappearance half-time of 1.5 +/- 0.2 hours, presumably reflecting rapid antigen- specific binding. The mean radiation absorbed doses (cGy/mCi131I administered) were as follows: marrow, 7.1 +/- 0.8; spleen, 10.8 +/- 1.4; liver, 2.7 +/- 0.2; lungs, 2.1 +/- 0.1; kidneys, 0.7 +/- 0.1; and total body, 0.4 +/- 0.03. Patients with acute myelogenous leukemia (AML) in relapse had a higher marrow dose (11.4 cGy/mCi) than those in remission (5.2 cGy/mCi; P = .001) because of higher uptake and longer retention of radionuclide in marrow. Twenty patients were treated with a dose of 131I estimated to deliver 3.5 Gy (level 1) to 7 Gy (level 3) to liver, with marrow doses of 4 to 30 Gy and spleen doses of 7 to 60 Gy, followed by 120 mg/kg cyclophosphamide (CY) and 12 Gy total body irradiation (TBI). Nine of 13 patients with AML or refractory anemia with excess blasts (RAEB) and two of seven with acute lymphocytic leukemia (ALL) are alive disease-free at 8 to 41 months (median, 17 months) after BMT. Toxicity has not been measurably greater than that of CY/TBI alone, and the maximum tolerated dose has not been reached. This study demonstrates that with the use of 131I-BC8 substantially greater doses of radiation can be delivered to hematopoietic tissues as compared with liver, lung, or kidney, which may improve the efficacy of marrow transplantation. 相似文献
35.
Graft-versus-host disease (GVHD) is currently encountered after bone marrow transplantation and transfusion. GVHD associated with transfusion (TA-GVHD) in apparently immunocompetent recipients has been recently reported with increasing frequency. A consistent finding in many of these cases is that the recipient received blood from a donor homozygous for one of the recipient's HLA haplotypes. However, the observed frequency of TA-GVHD is much lower than the estimated probability of this donor/recipient combination. The potential role of recipient immune responses in controlling TA-GVHD was investigated using an analogous murine model in which GVHD is induced by the injection of parental lymphoid cells into unirradiated F1 hybrid recipients. The effect of various immune manipulations of the recipient of GVHD induction was assessed by determining the number of donor lymphoid cells required to induce GVHD responses. Whereas depletion of recipient CD4+ cells increased the number of donor cells needed to induce GVHD, depletion of recipient CD8+ and natural killer cells resulted in fewer donor cells being needed to induce a GVHD response. These studies suggest a central role for functioning recipient CD8 and natural killer cells in the down-regulation of TA-GVHD development in recipients. 相似文献
36.
Sickle cell anemia patients have low erythropoietin levels for their degree of anemia 总被引:3,自引:1,他引:2
We have studied serum immunoreactive erythropoietin (SIE) levels in 28 patients with sickle cell anemia (SCA) without renal insufficiency and in 17 patients with nonhemoglobinopathy anemias of comparable severity using a sensitive radioimmunoassay procedure. An exponential relationship between SIE level and degree of anemia was noted in all patients. However, in nonhemoglobinopathy anemia, a sharp rise in the SIE level occurred as hemoglobin (Hb) levels fell below about 12 g/dL, whereas in sickle cell patients the increase was not marked until hemoglobin fell to about 9 g/dL. The response was more blunted in older SCA patients than in younger ones. A linear regression model relating SIE level to Hb level, presence/absence of SCA, and age explained 63% of the variation in SIE. We conclude that the serum erythropoietin levels in SCA increased at a lower hemoglobin concentration and are of a lower magnitude than that of the other anemias. 相似文献
37.
38.
39.
Kaplan LD; Shiramizu B; Herndier B; Hahn J; Meeker TC; Ng V; Volberding PA; McGrath MS 《Blood》1995,85(7):1727-1735
40.
Ng VL; Hwang KM; Reyes GR; Kaplan LD; Khayam-Bashi H; Hadley WK; McGrath MS 《Blood》1988,71(5):1397-1401
We observed a human immunodeficiency virus (HIV)-infected homosexual male with AIDS related complex (ARC) who had a serum globulin level of 80 g/L. Serum protein electrophoresis revealed a gamma globulin fraction of 40 g/L, of which 50% (20 g/L) was contained within a paraprotein spike, comprised predominantly of IgG kappa. This patient also had high titer anti-HIV antibodies in his serum, which were Western blot reactive at a final dilution of 1:500,000, and recognized gp120env, p66pol, p55gag, p53pol, p41gag, and p24gag. Because paraproteins in the past have been shown to be directed against specific antigens, we purified this patient's paraprotein using a modified high performance liquid chromatography (HPLC)-hydroxylapatite procedure and tested the purified paraprotein for anti-HIV antibody activity. The purified paraprotein retained anti-HIV antibody activity to a final dilution of 1:100,000, and recognized p66pol, p55gag, p53pol, p41gag, and p24gag. The recognition of both "gag" and "pol" gene products suggested that the purified paraprotein might not be monoclonal in origin. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) demonstrated that the purified paraprotein contained at least two immunoglobulin light chain species (Mol wt 30 to 33 Kd). Affinity chromatography of the purified paraprotein using a p24- Sepharose 4B matrix separated the "gag" and "pol" antibody activities. Immunoglobulin gene rearrangement analysis of a bone marrow aspirate (which contained 15% plasma cells) failed to reveal a clonal population of immunoglobulin producing cells. We conclude that this patient's paraprotein accounted for most of the anti-HIV activity present in whole serum, and that this paraprotein was not monoclonal in origin. 相似文献